Evidence map›Paper›PMID 39684692›Full record

ArticleInternational journal of molecular sciences2024

Circulating Cell-Free Microbial DNA Signatures and Plasma Soluble CD14 Level Are Associated with Clinical Outcomes of Anti-PD-1 Therapy in Advanced Melanoma Patients.

Bernadeta Drymel, Katarzyna Tomela, Łukasz Galus, Agnieszka Olejnik-Schmidt, Jacek Mackiewicz, Mariusz Kaczmarek, Andrzej Mackiewicz, Marcin Schmidt

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bernadeta DrymelDepartment of Biotechnology and Food Microbiology, Poznań University of Life Sciences, 60-627 Poznań, Poland.ORCID 0000-0001-6691-4444
Katarzyna TomelaDepartment of Cancer Immunology, Poznań University of Medical Sciences, 61-866 Poznań, Poland.ORCID 0000-0002-3622-7229
Łukasz GalusDepartment of Medical and Experimental Oncology, Institute of Oncology, Poznań University of Medical Sciences, 60-355 Poznań, Poland.
Agnieszka Olejnik-SchmidtDepartment of Biotechnology and Food Microbiology, Poznań University of Life Sciences, 60-627 Poznań, Poland.ORCID 0000-0002-5418-5632
Jacek MackiewiczDepartment of Medical and Experimental Oncology, Institute of Oncology, Poznań University of Medical Sciences, 60-355 Poznań, Poland.ORCID 0000-0002-0177-2972
Mariusz KaczmarekDepartment of Cancer Immunology, Poznań University of Medical Sciences, 61-866 Poznań, Poland.ORCID 0000-0002-6282-3251
Andrzej MackiewiczDepartment of Cancer Immunology, Poznań University of Medical Sciences, 61-866 Poznań, Poland.ORCID 0000-0001-5574-6609
Marcin SchmidtDepartment of Biotechnology and Food Microbiology, Poznań University of Life Sciences, 60-627 Poznań, Poland.ORCID 0000-0001-8417-2245

Funding

National Science Centre Poland 2017/25/B/NZ5/01949
6 · The paper itself

Abstract

An accumulating number of studies suggest the potential of circulating cell-free microbial DNA (cfmDNA) as a non-invasive biomarker in various diseases, including cancers. However, its value in the prediction or prognosis of clinical outcomes of immune checkpoint inhibitors (ICIs) is poorly explored. The circulating cfmDNA pool may also reflect the translocation of various microbial ligands to the circulatory system and may be associated with the increased release of soluble CD14 (sCD14) by myeloid cells. In the present study, blood samples were collected from advanced melanoma patients (

Indexed as

Biomarkers, TumorCell-Free Nucleic AcidsImmune Checkpoint InhibitorsLipopolysaccharide ReceptorsMelanomaAdultAgedFemaleHumansMaleMiddle AgedPrognosisProgrammed Cell Death 1 ReceptorProgression-Free SurvivalTreatment OutcomeBiomarkers, TumorCD14 protein, humanCell-Free Nucleic AcidsImmune Checkpoint InhibitorsLipopolysaccharide ReceptorsPDCD1 protein, humanProgrammed Cell Death 1 Receptoradvanced melanomacirculating cell-free microbial DNAimmune checkpoint inhibitorsplasma soluble CD14

Identifiers

PMID39684692
PMCPMC11641495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.